Arrowhead Pharmaceuticals, Inc. - Form 4 Filing

This filing details transactions made by Daniel Joseph Apel, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. On April 22, 2026, Mr. Apel sold a total of 13,095 shares of common stock. These sales were conducted under a Rule 10b5-1 trading plan and also included shares to cover tax withholding obligations. The sales occurred at weighted average prices, with specific ranges noted for each transaction: $69.50 to $70.23 for 3,208 shares, $70.29 to $70.51 for 1,157 shares, and $71.55 to $71.97 for 8,730 shares. Following these transactions, Mr. Apel directly owns 162,905 shares, which includes previously reported shares underlying Restricted Stock Units, some of which are still subject to vesting conditions.